Daiichi Sankyo (OTCMKTS:DSNKY – Get Free Report) announced its earnings results on Friday. The company reported $0.24 earnings per share for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01), Zacks reports. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo had a return on equity of 15.75% and a net margin of 12.32%. Daiichi Sankyo updated its FY 2026 guidance to 0.870-0.870 EPS.
Daiichi Sankyo Price Performance
Shares of OTCMKTS:DSNKY opened at $16.14 on Friday. The company has a 50 day moving average of $16.51 and a 200 day moving average of $17.73. The company has a current ratio of 2.42, a quick ratio of 1.64 and a debt-to-equity ratio of 0.18. Daiichi Sankyo has a 12 month low of $14.98 and a 12 month high of $27.50. The stock has a market cap of $30.07 billion, a P/E ratio of 18.77, a P/E/G ratio of 2.83 and a beta of -0.17.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on DSNKY. Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. Jefferies Financial Group lowered Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday. Two analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the company has an average rating of “Hold”.
Daiichi Sankyo Company Profile
Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
Featured Stories
- Five stocks we like better than Daiichi Sankyo
- Netflix’s Big Sell-Off May Be Sending the Wrong Signal
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
Receive News & Ratings for Daiichi Sankyo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daiichi Sankyo and related companies with MarketBeat.com's FREE daily email newsletter.
